Effect of Tocilizumab on "Ventilator Free Days" Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis.

Ahmed F MadyBasheer AbdulrahmanShahzad A MumtazMohammed A Al-OdatAhmed KuhailRehab AltoraifiRayan AlshaeAbdulrahman M AlharthyDimitrios KarakitsosWaleed Th Aletreby

Published in: Romanian journal of anaesthesia and intensive care (2023)

Tocilizumab may improve the composite outcome of ventilator-free days at day 28 among mechanically ventilated SARS-CoV-2 patients; it is associated with significantly longer actual ventilator-free periods, and insignificantly lower mortality and higher superinfection.

Keyphrases

sars cov
end stage renal disease
chronic kidney disease
newly diagnosed
acute respiratory distress syndrome
rheumatoid arthritis
prognostic factors
mechanical ventilation
intensive care unit
cardiovascular disease
type diabetes
coronavirus disease
rheumatoid arthritis patients
patient reported
disease activity